Nueclear Onco Profile Sharmila B Ghag (53Y/F) Om Shivam Seva Mandal Prem Nagar Teen Jongrin Goregaon West Mumbai - 400104

PROCESSED AT :
Thyrocare
D-37/1,TTC MIDC,Turbhe,
Navi Mumbai-400 703
NAME : SHARMILA B GHAG (53Y/F) SAMPLE COLLECTED AT :

OM SHIVAM SEVA MANDAL PREM NAGAR TEEN
REF. BY : NUECLEAR ONCO PROFILE
JONGRIN GOREGAON WEST MUMBAI - 400104
TEST ASKED : BIOT PROFILE,BLOOD ELEMENT ANALYSIS PROFILE,CA
15.3,CA 19.9,CA-125,CEA,HBA,HEMOGRAM - 6 PART
TEST NAME TECHNOLOGY VALUE UNITS

HbA1c - (HPLC - NGSP Certified)
H.P.L.C 7.6 %
Reference Range :
Reference Range: As per ADA Guidelines Guidance For Known Diabetics
Below 5.7% : Normal Below 6.5% : Good Control

5.7% - 6.4% : Prediabetic 6.5% - 7% : Fair Control
>=6.5% : Diabetic 7.0% - 8% : Unsatisfactory Control
>8% : Poor Control
Method : Fully Automated H.P.L.C. using Biorad Variant II Turbo, NGSP Certified.
AVERAGE BLOOD GLUCOSE (ABG) CALCULATED 171 mg/dl
Reference Range :
90 - 120 mg/dl : Good Control

121 - 150 mg/dl : Fair Control
151 - 180 mg/dl : Unsatisfactory Control
> 180 mg/dl : Poor Control
Method : Derived from HBA1c values

Please correlate with clinical conditions.
Sample Collected on (SCT) :26 Jul 2019 09:30

Sample Received on (SRT) : 27 Jul 2019 03:13
Report Released on (RRT) : 27 Jul 2019 07:35
Sample Type : EDTA
Dr.Prachi Sinkar MD(Path) Dr.Caesar Sengupta MD(Micro)
Labcode : 2607052876/SMT00
Page : 1 of 14
Barcode : O0047197
PROCESSED AT :
Thyrocare
Navi Mumbai-400 703

TEST NAME VALUE UNITS REFERENCE RANGE

TOTAL LEUCOCYTES COUNT 7.94 X 10³ / µL 4.0-10.0
NEUTROPHILS 54.5 % 40-80
LYMPHOCYTE PERCENTAGE 39.3 % 20.0-40.0
MONOCYTES 3.8 % 0.0-10.0
EOSINOPHILS 1.9 % 0.0-6.0
BASOPHILS 0.2 % <2
IMMATURE GRANULOCYTE PERCENTAGE(IG%) 0.3 % 0.0-0.4
NEUTROPHILS - ABSOLUTE COUNT 4.34 X 10³ / µL 2.0-7.0
LYMPHOCYTES - ABSOLUTE COUNT 3.12 X 10³ / µL 1.0-3.0
MONOCYTES - ABSOLUTE COUNT 0.3 X 10³ / µL 0.2-1.0
BASOPHILS - ABSOLUTE COUNT 0.02 X 10³ / µL 0.02-0.1
EOSINOPHILS - ABSOLUTE COUNT 0.15 X 10³ / µL 0.02-0.5
IMMATURE GRANULOCYTES(IG) 0.03 X 10³ / µL 0.0-0.3
TOTAL RBC 4.03 X 10^6/µL 3.9-4.8
NUCLEATED RED BLOOD CELLS Nil X 10³ / µL <0.01
NUCLEATED RED BLOOD CELLS % Nil % <0.01
HEMOGLOBIN 12.1 g/dL 12.0-15.0
HEMATOCRIT(PCV) 37.9 % 36.0-46.0
MEAN CORPUSCULAR VOLUME(MCV) 94 fL 83.0-101.0
MEAN CORPUSCULAR HEMOGLOBIN(MCH) 30 pq 27.0-32.0
MEAN CORP.HEMO.CONC(MCHC) 31.9 g/dL 31.5-34.5
RED CELL DISTRIBUTION WIDTH - SD(RDW-SD) 63.5 fL 39.0-46.0
RED CELL DISTRIBUTION WIDTH (RDW-CV) 18.8 % 11.6-14.0
PLATELET DISTRIBUTION WIDTH(PDW) 10.1 fL 9.6-15.2
MEAN PLATELET VOLUME(MPV) 9.5 fL 6.5-12
PLATELET COUNT 348 X 10³ / µL 150-400
PLATELET TO LARGE CELL RATIO(PLCR) 20 % 19.7-42.4
PLATELETCRIT(PCT) 0.33 % 0.19-0.39
Remarks : ALERT !!! Anisocytosis
Please Correlate with clinical conditions.

Method : Fully automated bidirectional analyser (6 Part Differential SYSMEX XN-1000)
(This device performs hematology analyses according to the Hydrodynamic Focussing (DC method), Flow
Cytometry Method (using a semiconductor laser), and SLS- hemoglobin method)
Sample Collected on (SCT) : 26 Jul 2019 09:30

Sample Type : EDTA
Labcode : 2607052876/SMT00
Page : 2 of 14
Barcode : O0047197
PROCESSED AT :
Thyrocare
Navi Mumbai-400 703

REF. BY : NUECLEAR ONCO PROFILE OM SHIVAM SEVA MANDAL PREM NAGAR TEEN JONGRIN
GOREGAON WEST MUMBAI - 400104
TEST NAME TECHNOLOGY VALUE UNITS NORMAL RANGE

ARSENIC ICP-MS 4.73 µg/l <5
CADMIUM ICP-MS 0.96 µg/l < 1.5
MERCURY ICP-MS 0.84 µg/l <5
LEAD ICP-MS 21.6 µg/l < 150
CHROMIUM ICP-MS 0.54 µg/l < 30
BARIUM ICP-MS 2.48 µg/l < 30
COBALT ICP-MS 0.31 µg/l 0.10 - 1.50
CAESIUM ICP-MS 2.31 µg/l <5
SELENIUM ICP-MS 250.93 µg/l 60 - 340
Method :
ICP - MASS SPECTROMETRY
Note:Reference range has been obtained after considering 95% population as cutoff.

Sample Type : EDTA
Labcode : 2607052876/SMT00 Dr.Prachi Sinkar MD(Path) Dr.Caesar Sengupta MD(Micro)
Barcode : O0047197 Page : 3 of 14
PROCESSED AT :
Thyrocare
Navi Mumbai-400 703


CA 15.3 C.M.I.A 20.8 U/ml
Reference Range :-
Less than 31.3 U/ml
Clinical Significance:
CA 15.3 is elevated in about 30% of women with localized breast cancer and in about 75% of those with
metastatic breast cancer. CA 15.3 also may be elevated in Healthy people and in individuals with other cancers or
diseases, Such as Colorectal Cancer, Lung Cancer, Cirrhosis, Hepatitis, and Benign Breast Disease. In General, the
higher the CA 15-3 level the more advanced the Breast Cancer and the larger the Tumor Burden.
Specifications:
Precision: Intra Assay (%CV): 4.7 %, Inter Assay (%CV): 5.1 %; Sensitivity:<=0.5 U/ml
External Quality Control Program Participation:
College of American Pathologists (CAP): Tumor Markers Survey; CAP Certification Number: 7193855-01
Kit Validation References:
Reddish MA, Helbrecht N, Almeida AF, ET AL. Epitope mapping of MAB B27.29 Within the peptide core for the
Malignant Breast Varcinoma-Associated mucin antigen coded for by the human Muc-1 Gene. J Tumor Marker Oncol.
1992, 7:19-27.
Method:- FULLY AUTOMATED CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY

Sample Type : SERUM Dr.Prachi Sinkar MD(Path) Dr.Caesar Sengupta MD(Micro)
Labcode : 2607053232/SMT00
Page : 4 of 14
Barcode : N9461098
PROCESSED AT :
Thyrocare
Navi Mumbai-400 703


CA 19.9 C.M.I.A 97.3 U/mL
Reference Range :-
Adults : Less than 37.0 U/mL
CA 19-9 is elevated in most patients with advanced Pancreatic Cancer, But it may also be elevated in other
cancers, conditions, and diseases such as Colorectal cancer, Lung Cancer, Gall Bladder Cancer, Gallstones,
Pancreatitis, Cystic Fibrosis, and Liver Disease. Bile duct obstruction may also cause very high CA 19-9 levels. Very
small amounts of CA 19-9 may also be found in healthy patients.
For Diagnostic Purpose, Results should always be assessed in conjunction with the patients medical history,
Clinical Examination and other findings.
Specifications:
Intra assay (%CV): 8.0 %, Inter assay(%CV) : 8.5% & Sensitivity: 2.0 U/ml
Steinberg W. The clinical utility of the CA 19.9 Tumor-Associated antigen. AM J Gastroenterol 1990; 85(4): 350

Labcode : 2607053232/SMT00
Page : 5 of 14
Barcode : N9461098
PROCESSED AT :
Thyrocare
Navi Mumbai-400 703


CA-125 C.M.I.A 12.1 U/ml
Reference Range :-
Less than 35.0 U/ml
CA-125 is used to monitor therapy during treatment for Ovarian Cancer. CA125 is also to detect or monitor
whether there is a recurrence of cancer or malignancy after surgical removal of tumor or radiation therapy or
chemotherapy (antineoplastic drugs). This test is sometimes used to follow High-Risk women who have a family
history of Ovarian Cancer. CA-125 may normally be increased in early pregnancy and during menstruation. It can
also be increased in diseases such as Pelvic Inflammatory Disease or Endometriosis and sometimes in Hepatitis
and Cirrhosis of the liver.
Specifications:
Precision: Intra Assay (%CV): 3.2 %, Inter Assay (%CV): 4.3%; Sensitivity: <1.0 U/ml
Mackey SE, Creasman WT. Ovarian Cancer Screening. J. Clin Oncol 1995; 13(3); 783 - 93.

Labcode : 2607053232/SMT00
Page : 6 of 14
Barcode : N9461098
PROCESSED AT :
Thyrocare
Navi Mumbai-400 703


CARCINO EMBRYONIC ANTIGEN (CEA) C.M.I.A 5.7 ng/ml
Reference Range :-
< 5.00 ng/mL
Clinical Significance :
CEA is often used to monitor patients with cancers of the gastrointestinal tract (GI). Increased CEA levels can
indicate some Non-Cancer related conditions, Such as some forms of inflammation, Cirrhosis, and Peptic Ulcer.
Also, Smokers tend to have Higher CEA levels than Non-Smokers. When cancer spreads to other organs, CEA
levels rise and may be present in other types of bodily fluids besides blood.
For Diagnostic Purpose, Results should always be assessed in Conjunction with the patients medical history,
clinical examination and other findings.
Specifications:
Precision: Intra Assay (%CV): 3.6 %, Inter Assay (%CV): 4.0 %; Sensitivity: 0.5 ng/ml
College of American Pathologists (CAP): Ligand Assay (General) Survey; CAP Certification Number: 7193855-01
Statland Be, Winkel P. Neoplasia. In: Kaplan LA, Resc AJ, Editors. Clinical Chemistry, Theory, Analysis and
Correlation. 2nd Ed. St. Louis: Cv Mosby, 1989.p 734-5.

Labcode : 2607053232/SMT00
Page : 7 of 14
Barcode : N9461098
PROCESSED AT :
Thyrocare
Navi Mumbai-400 703

IRON PHOTOMETRY 79.3 µg/dl

Reference Range :
Male : 65 - 175
Female : 50 - 170
Method : Ferrozine method without deproteinization
TOTAL IRON BINDING CAPACITY (TIBC) PHOTOMETRY 317 µg/dl
Reference Range :
Male: 225 - 535 µg/dl Female: 215 - 535 µg/dl
Method : Spectrophotometric Assay
% TRANSFERRIN SATURATION CALCULATED 25.02 %
Reference Range :
13 - 45
Method : Derived from IRON and TIBC values
Sample Collected on (SCT) :26 Jul 2019 09:30

Sample Type : SERUM
Labcode : 2607053232/SMT00
Page : 8 of 14
Barcode : N9461098
PROCESSED AT :
Thyrocare
Navi Mumbai-400 703


ALKALINE PHOSPHATASE PHOTOMETRY 81.2 U/L 45 - 129
BILIRUBIN - TOTAL PHOTOMETRY 0.95 mg/dl 0.3-1.2
BILIRUBIN -DIRECT PHOTOMETRY 0.11 mg/dl < 0.3
BILIRUBIN (INDIRECT) CALCULATED 0.84 mg/dl 0-0.9
ASPARTATE AMINOTRANSFERASE (SGOT ) PHOTOMETRY 23.9 U/l < 31
ALANINE TRANSAMINASE (SGPT) PHOTOMETRY 26.2 U/l < 34
GAMMA GLUTAMYL TRANSFERASE (GGT) PHOTOMETRY 60.7 U/l < 38
ALBUMIN - SERUM PHOTOMETRY 3.8 gm/dl 3.2-4.8
PROTEIN - TOTAL PHOTOMETRY 6.64 gm/dl 5.7-8.2
SERUM ALB/GLOBULIN RATIO CALCULATED 1.34 Ratio 0.9 - 2
Method :
ALKP - Modified IFCC method
BILT - Vanadate Oxidation
BILD - Vanadate Oxidation
BILI - Derived from serum Total and Direct Bilirubin values
SGOT - IFCC* Without Pyridoxal Phosphate Activation
SGPT - IFCC* Without Pyridoxal Phosphate Activation
GGT - Modified IFCC method
SALB - Albumin Bcg¹method (Colorimetric Assay Endpoint)
PROT - Biuret Method
A/GR - Derived from serum Albumin and Protein values

Sample Type : SERUM
Barcode : N9461098 Page : 9 of 14
PROCESSED AT :
Thyrocare
Navi Mumbai-400 703


LDL CHOLESTEROL CALCULATED 192 mg% 85 - 130
THYROID STIMULATING HORMONE (TSH) C.M.I.A 2.94 µIU/ml 0.35 - 4.94
Method :
LDLC - DERIVED FROM CHOLESTEROL AND TRIGLYCERIDE VALUES
TSH - Fully Automated Chemi Luminescent Microparticle Immunoassay

Sample Type : SERUM
PROCESSED AT :
Thyrocare
Navi Mumbai-400 703


CALCIUM PHOTOMETRY 10.24 mg/dl 8.8-10.6
BLOOD UREA NITROGEN (BUN) PHOTOMETRY 12.29 mg/dl 7 - 25
CREATININE - SERUM PHOTOMETRY 0.69 mg/dl 0.5-0.8
URIC ACID PHOTOMETRY 6.73 mg/dl 3.2 - 6.1
BUN / SR.CREATININE RATIO CALCULATED 17.81 Ratio 9:1-23:1
Method :
CALC - Arsenazo III Method, End Point.
BUN - Kinetic UV Assay.
SCRE - Creatinine Enzymatic method
URIC - Uricase / Peroxidase Method
B/CR - Derived from serum Bun and Creatinine values

Sample Type : SERUM
PROCESSED AT :
Thyrocare
Navi Mumbai-400 703


TOTAL CHOLESTEROL PHOTOMETRY 286 mg/dl 125-200
HDL CHOLESTEROL - DIRECT PHOTOMETRY 40 mg/dl 35-80
TRIGLYCERIDES PHOTOMETRY 268 mg/dl 25-200
TC/ HDL CHOLESTEROL RATIO CALCULATED 7.1 Ratio 3-5
LDL / HDL RATIO CALCULATED 4.8 Ratio 1.5-3.5
VLDL CHOLESTEROL CALCULATED 53.68 mg/dl 5 - 40
NON-HDL CHOLESTEROL CALCULATED 245.9 mg/dl < 160
Method :
CHOL - CHOD POD Method
HCHO - Enzyme selective protection method
TRIG - Enzymatic Colorimetric Method (GPO) [Highly influenced by level of fasting]
TC/H - Derived from serum Cholesterol and Hdl values
LDL/ - Derived from serum HDL and LDL Values
VLDL - Derived from serum Triglyceride values
NHDL - Derived from serum Cholesterol and HDL values
*REFERENCE RANGES AS PER NCEP ATP III GUIDELINES:
TOTAL CHOLESTEROL (mg/dl) HDL (mg/dl) LDL (mg/dl) TRIGLYCERIDES (mg/dl)
DESIRABLE <200 LOW <40 OPTIMAL <100 NORMAL <150
BORDERLINE HIGH 200-239 HIGH >60 NEAR OPTIMAL 100-129 BORDERLINE HIGH 150-199
HIGH >240 BORDERLINE HIGH 130-159 HIGH 200-499
HIGH 160-189 VERY HIGH >500

VERY HIGH >190
Alert !!! 10-12 hours fasting is mandatory for lipid parameters. If not, values might fluctuate.

Sample Type : SERUM
PROCESSED AT :
Thyrocare
Navi Mumbai-400 703


EST. GLOMERULAR FILTRATION RATE (eGFR) CALCULATED 99 mL/min/1.73 m2
Reference Range :-
> = 90 : Normal
60 - 89 : Mild Decrease
45 - 59 : Mild to Moderate Decrease
30 - 44 : Moderate to Severe Decrease
15 - 29 : Severe Decrease
Clinical Significance
The normal serum creatinine reference interval does not necessarily reflect a normal GFR for a patient. Because
mild and moderate kidney injury is poorly inferred from serum creatinine alone. Thus, it is recommended for clinical
laboratories to routinely estimate glomerular filtration rate (eGFR), a “gold standard” measurement for
assessment of renal function, and report the value when serum creatinine is measured for patients 18 and older,
when appropriate and feasible. It cannot be measured easily in clinical practice, instead, GFR is estimated from
equations using serum creatinine, age, race and sex. This provides easy to interpret information for the doctor and
patient on the degree of renal impairment since it approximately equates to the percentage of kidney function
remaining. Application of CKD-EPI equation together with the other diagnostic tools in renal medicine will further
improve the detection and management of patients with CKD.
Reference
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate
glomerular filtration rate. Ann Intern Med. 2009;150(9):604-12.
Method:- CKD-EPI Creatinine Equation
~~ End of report ~~

Labcode : 2607053232/SMT00
Page : 13 of 14
Barcode : N9461098
CONDITIONS OF REPORTING
v The reported results are for information and interpretation of the referring doctor only.
v It is presumed that the tests performed on the specimen belong to the patient; named or identified.
v Results of tests may vary from laboratory to laboratory and also in some parameters from time to time for the
same patient.
v Should the results indicate an unexpected abnormality, the same should be reconfirmed.
v Only such medical professionals who understand reporting units, reference ranges and limitations of
technologies should interpret results.
v This report is not valid for medico-legal purpose.
v Neither Thyrocare, nor its employees/representatives assume any liability, responsibility for any loss or damage
that may be incurred by any person as a result of presuming the meaning or contents of the report.
EXPLANATIONS
v Majority of the specimen processed in the laboratory are collected by Pathologists and Hospitals we call them
as "Clients".
v Name - The name is as declared by the client and recored by the personnel who collected the specimen.
v Ref.Dr - The name of the doctor who has recommended testing as declared by the client.
v Labcode - This is the accession number in our laboratory and it helps us in archiving and retrieving the data.
v Barcode - This is the specimen identity number and it states that the results are for the specimen bearing
the barcode (irrespective of the name).
v SCP - Specimen Collection Point - This is the location where the blood or specimen was collected as declared by
the client.
v SCT - Specimen Collection Time - The time when specimen was collected as declared by the client.
v SRT - Specimen Receiving Time - This time when the specimen reached our laboratory.
v RRT - Report Releasing Time - The time when our pathologist has released the values for Reporting.
v Reference Range - Means the range of values in which 95% of the normal population would fall.
SUGGESTIONS
v Values out of reference range requires reconfirmation before starting any medical treatment.
v Retesting is needed if you suspect any quality shortcomings.
v Testing or retesting should be done in accredited laboratories.
v For suggestions, complaints or feedback, write to us at info@thyrocare.com or call us on
022-3090 0000 / 4125 2525
v SMS:<Labcode No.> to 9870666333
Page : 14 of 14

Nueclear Onco Profile Sharmila B Ghag (53Y/F) Om Shivam Seva Mandal Prem Nagar Teen Jongrin Goregaon West Mumbai - 400104

Uploaded by

Copyright:

Available Formats

Nueclear Onco Profile Sharmila B Ghag (53Y/F) Om Shivam Seva Mandal Prem Nagar Teen Jongrin Goregaon West Mumbai - 400104

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Nueclear Onco Profile Sharmila B Ghag (53Y/F) Om Shivam Seva Mandal Prem Nagar Teen Jongrin Goregaon West Mumbai - 400104

Uploaded by

Copyright:

Available Formats

PROCESSED AT :

NAME : SHARMILA B GHAG (53Y/F) SAMPLE COLLECTED AT :

TEST NAME TECHNOLOGY VALUE UNITS

Reference Range: As per ADA Guidelines Guidance For Known Diabetics

Below 5.7% : Normal Below 6.5% : Good Control

90 - 120 mg/dl : Good Control

Method : Derived from HBA1c values

Sample Collected on (SCT) :26 Jul 2019 09:30

NAME : SHARMILA B GHAG (53Y/F) SAMPLE COLLECTED AT :

TEST NAME VALUE UNITS REFERENCE RANGE

Please Correlate with clinical conditions.

Sample Collected on (SCT) : 26 Jul 2019 09:30

NAME : SHARMILA B GHAG (53Y/F) SAMPLE COLLECTED AT :

TEST NAME TECHNOLOGY VALUE UNITS NORMAL RANGE

Sample Collected on (SCT) : 26 Jul 2019 09:30

NAME : SHARMILA B GHAG (53Y/F) SAMPLE COLLECTED AT :

TEST NAME TECHNOLOGY VALUE UNITS

Less than 31.3 U/ml

External Quality Control Program Participation:

Kit Validation References:

Sample Collected on (SCT) : 26 Jul 2019 09:30

NAME : SHARMILA B GHAG (53Y/F) SAMPLE COLLECTED AT :

TEST NAME TECHNOLOGY VALUE UNITS

Adults : Less than 37.0 U/mL

External Quality Control Program Participation:

Kit Validation References:

Sample Collected on (SCT) : 26 Jul 2019 09:30

NAME : SHARMILA B GHAG (53Y/F) SAMPLE COLLECTED AT :

TEST NAME TECHNOLOGY VALUE UNITS

Less than 35.0 U/ml

External Quality Control Program Participation:

Kit Validation References:

Sample Collected on (SCT) : 26 Jul 2019 09:30

NAME : SHARMILA B GHAG (53Y/F) SAMPLE COLLECTED AT :

TEST NAME TECHNOLOGY VALUE UNITS

< 5.00 ng/mL

External Quality Control Program Participation:

Kit Validation References:

Sample Collected on (SCT) : 26 Jul 2019 09:30

NAME : SHARMILA B GHAG (53Y/F) SAMPLE COLLECTED AT :

TEST NAME TECHNOLOGY VALUE UNITS

IRON PHOTOMETRY 79.3 µg/dl

Sample Collected on (SCT) :26 Jul 2019 09:30

NAME : SHARMILA B GHAG (53Y/F) SAMPLE COLLECTED AT :

TEST NAME TECHNOLOGY VALUE UNITS NORMAL RANGE

Sample Collected on (SCT) : 26 Jul 2019 09:30

NAME : SHARMILA B GHAG (53Y/F) SAMPLE COLLECTED AT :

TEST NAME TECHNOLOGY VALUE UNITS NORMAL RANGE

Sample Collected on (SCT) : 26 Jul 2019 09:30

NAME : SHARMILA B GHAG (53Y/F) SAMPLE COLLECTED AT :

TEST NAME TECHNOLOGY VALUE UNITS NORMAL RANGE

Sample Collected on (SCT) : 26 Jul 2019 09:30

NAME : SHARMILA B GHAG (53Y/F) SAMPLE COLLECTED AT :

TEST NAME TECHNOLOGY VALUE UNITS NORMAL RANGE

TOTAL CHOLESTEROL (mg/dl) HDL (mg/dl) LDL (mg/dl) TRIGLYCERIDES (mg/dl)

DESIRABLE <200 LOW <40 OPTIMAL <100 NORMAL <150

HIGH >240 BORDERLINE HIGH 130-159 HIGH 200-499

HIGH 160-189 VERY HIGH >500

Sample Collected on (SCT) : 26 Jul 2019 09:30